A novel competitive fluorescent multiplex STR polymorphism assay for rapid, reliable and single-tube screening of 22q11.2 copy-number aberrations.
Copy-number aberrations of the 22q11.2 region can lead to varied resulting and complex phenotypes. Routine screening for these common constitutional chromosomal abnormalities requires powerful tools. A competitive fluorescent multiplex STR polymorphism assay (CFMSA) was built for detecting these aberrations. With the introduction of an internal reference and distinguishable STR polymorphism markers, this competitive fluorescent multiplex STR polymorphism assay provides complementary information about polymorphism and gene dosage in one tube simultaneously, thereby enhancing the assay sensitivity. It was first tested in 110 normal controls, and was proven to have highly polymorphic and reliable gene dosage information. Then, 476 subjects with congenital heart defect were screened according to the testing strategy of the American Heart Association, and 17 deletions and 1 duplication of 22q11.2 were correctly identified. It is expected that this assay will serve as a cost-effective alternative to existing assays for routine, large-scale screening in all at-risk individuals with either deletion or duplication in 22q11.2.
Yang
Chi
C
Department of Pathology, Nanjing University Medical School, Nanjing, P. R. China.
Shen
Li
L
Xu
Zhengfeng
Z
Wu
Xiaojian
X
Mo
Xuming
X
Zhang
Jingjing
J
Wang
Dongjin
D
Wang
Yaping
Y
Peng
Yuzhu
Y
Cao
Li
L
Jiang
Yongzhong
Y
Gu
Haitao
H
Chen
Shilin
S
Bian
Xuming
X
Liu
Juntao
J
Qiao
Di
D
Yi
Long
L
D002869:Chromosome Aberrations; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics*; D005333:Fetus / Q000378:metabolism; D018628:Gene Dosage; D005820:Genetic Testing / Q000379:methods; D006330:Heart Defects, Congenital / Q000175:diagnosis*; D006801:Humans; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D011110:Polymorphism, Genetic; D013050:Spectrometry, Fluorescence / Q000379:methods*